D.G. Armstrong, T.W. Tan, A.J. Boulton, S.A. Bus. Diabetic foot ulcers: A review. Journal of the American Medical Association 2023; 330(1): 62-75.

R. Reardon, D. Simring, B. Kim, J. Mortensen, D. Williams, A. Leslie. The diabetic foot ulcer. Australian Journal of General Practice 2020; 49(5): 250-5.

J. Musuuza, B.L. Sutherland, S. Kurter, P. Balasubramanian, C.M. Bartels, M.B. Brennan. A systematic review of multidisciplinary teams to reduce major amputations for patients with diabetic foot ulcers. Journal of Vascular Surgery 2020; 71(4): 1433-1446.e3.

G.L. Tao, L.S. Zheng, Z.Y. Wang, Y.P. Xu, X.G. Zhong, H. Wang. Clinical characteristics and risk factors of diabetic foot ulcers with PAD. European Review for Medical and Pharmacological Sciences 2023; 27(23): 11412-20.

M.S. Al-Nimer, I.I. Latif, T.M. Jawad. Effects of sitagliptin versus empagliflozin on the stress hyperglycemic ratio in peoplewith type 2 diabetes: an open-label, randomized controlled trial. Clinical Diabetology 2024; 13(3): 156-63.

Ö.F. Demir, A.D. Balyimez. The relationship between acute-to-chronic glycemic ratio and SYNTAX score in diabetic patients presenting with acute coronary syndrome. The International Journal of Angiology : Official Publication of the International College of Angiology, Inc 2023; 33(1): 15-21.

J. Yang, Y. Zheng, C. Li, J. Gao, X. Meng, K. Zhang. The impact of the stress hyperglycemia ratio on short-term and long-term poor prognosis in patients with acute coronary syndrome: insight from a large cohort study in Asia. Diabetes Care 2022; 45(4): 947-56.

J. Liu, Y. Zhou, H. Huang, R. Liu, Y. Kang, T. Zhu. Impact of stress hyperglycemia ratio on mortality in patients with critical acute myocardial infarction: insight from american MIMIC-IV and the chinese CIN-II study. Cardiovascular Diabetology 2023; 22(1): 281.

K. Cui, R. Fu, J. Yang, H. Xu, D. Yin, W. Song, CAMI Registry Investigators. The impact of fasting stress hyperglycemia ratio, fasting plasma glucose and hemoglobin A1c on in-hospital mortality in patients with and without diabetes: findings from the China acute myocardial infarction registry. Cardiovascular Diabetology 2023; 22(1): 165.

V. Fejfarová, A. Jirkovská, M. Dubský, F. Game, J. Vydláková, A. Sekerková. An Alteration of lymphocytes subpopulations and immunoglobulins levels in patients with diabetic foot ulcers infected particularly by resistant pathogens. Journal of Diabetes Research 2016; 2016: 2356870.

W.Q. Zhang, W. Tang, S.Q. Hu, X.L. Fu, H. Wu, W.Q. Shen. C-reactive protein and diabetic foot ulcer infections: A meta-analysis. Journal of Tissue Viability 2022; 31(3): 537-43.

K. Bao, H. Huang, G. Huang, J. Wang, Y. Liao, Y. Pan. Platelet-to-hemoglobin ratio as a valuable predictor of long-term all-cause mortality in coronary artery disease patients with congestive heart failure. BMC Cardiovascular Disorders 2021; 21(1): 618.

S.Y. Hung, Y.Y. Huang, L.A. Hsu, C.C. Chen, H.M. Yang, J.H. Sun. Treatment for diabetic foot ulcers complicated by major cardiac events. Canadian Journal of Diabetes 2015; 39(3): 183-7.

A. Fabbri, G. Marchesini, B. Benazzi, A. Morelli, D. Montesi, C. Bini. Stress hyperglycemia and mortality in subjects with diabetes and sepsis. Critical Care Explorations 2020; 2(7): e0152.

M. Fang, J. Hu, Y. Jeon, K. Matsushita, E. Selvin, C.W. Hicks. Diabetic foot disease and the risk of major clinical outcomes. Diabetes Research and Clinical Practice 2023; 202: 110778.

B. Lioy, R.J. Webb, F. Amirabdollahian. Amir abdollahian F. The Association between the atherogenic index of plasma and cardiometabolic risk factors: A review. Healthcare (Basel) 2023; 11(7): 966.

O. Kilic, I. Buber, F. Kahraman. Predicting the severity of coronary artery disease: can the leukocyte glucose index be used?. Journal of the College of Physicians and Surgeons-Pakistan : JCPSP 2022; 32(12): 1519-23.

P. Zhang, J. Lu, Y. Jing, S. Tang, D. Zhu, Y. Bi. Global epidemiology of diabetic foot ulceration: a systematic review and meta-analysis. Annals of Medicine 2017; 49(2): 106-16.

P. Nehring, B. Mrozikiewicz-Rakowska, M. Krzyżewska, A. Sobczyk-Kopcio\l, R. P\loski, G. Broda. Diabetic foot risk factors in type 2 diabetes patients: a cross-sectional case control study. Journal of Diabetes and Metabolic Disorders 2014; 13(1): 79.

A. Ardelean, A.A. Neamtu, D.F. Balta, C. Neamtu, D. Goldis, M. Rosu. Lipid profile paradox: investigating improved lipid levels in diabetic mellitus patients with foot ulcer infections-A prospective descriptive study. Diagnostics (Basel) 2023; 13(23): 3531.

T.Y. Wang, W.L. Chang, C.Y. Wei, C.H. Liu, R.C. Tzeng, P.Y. Chiu. Cholesterol paradox in older people with type 2 diabetes mellitus regardless of lipid-lowering drug use: A cross-sectional cohort study. Nutrients 2023; 15(14): 3270.

B. Wang, Z. Guo, H. Li, Z. Zhou, H. Lu, M. Ying. Non-HDL cholesterol paradox and effect of underlying malnutrition in patients with coronary artery disease: A 41,182 cohort study. Clinical Nutrition : Official Journal of the European Society of Parenteral and Enteral Nutrition 2022; 41(3): 723-30.

M.A. González-Gay, C. González-Juanatey. Inflammation and lipid profile in rheumatoid arthritis: bridging an apparent paradox. Annals of the Rheumatic Diseases 2014; 73(7): 1281-3.

F. Urbano, M. Bugliani, A. Filippello, A. Scamporrino, S. Di Mauro, A. Di Pino. Atorvastatin but not pravastatin impairs mitochondrial function in human pancreatic islets and rat β-Cells. Scientific reports 2017; 7(1): 11863.

U. Galicia-Garcia, S. Jebari, A. Larrea-Sebal, K.B. Uribe, H. Siddiqi, H. Ostolaza. Statin Treatment-induced development of type 2 diabetes: from clinical evidence to mechanistic insights. International Journal of Molecular Sciences 2020; 21(13): 4725.

A. Kelem, T. Adane, E. Shiferaw. Insulin resistance-induced platelet hyperactivity and a potential biomarker role of platelet parameters: A narrative review. Diabetes, Metabolic Syndrome and Obesity 2023; 16: 2843-53.

A. Nusca, D. Tuccinardi, S. Pieralice, S. Giannone, M. Carpenito, L. Monte. Platelet effects of anti-diabetic therapies: new perspectives in the management of patients with diabetes and cardiovascular disease. Frontiers in Pharmacology 2021; 12: